FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
Rhea-AI Summary
Royal Philips (NYSE: PHG) received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered solution that provides real-time visualization and navigation during minimally invasive mitral transcatheter edge-to-edge repair (M-TEER).
DeviceGuide auto-tracks the Edwards PASCAL Ace device, integrates live 3D echo and X-ray via Azurion and EPIQ platforms, was developed with Edwards Lifesciences, and will be showcased at ACC 2026. Commercial availability is subject to market release and regional regulatory clearance.
Positive
- FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide
- Real-time AI tracking of the Edwards PASCAL Ace repair device
- Integration with Philips Azurion and EPIQ for fused echo-fluoro imaging
Negative
- Commercial availability subject to market release and local regulatory clearance
- Intended only for use with Edwards PASCAL Ace device
- Availability outside the U.S. varies by country and regulatory status
Key Figures
Market Reality Check
Peers on Argus
PHG gained 2.66% while key Medical Devices peers were mixed: ZBH up 0.84%, STE, DXCM and SNN slightly down, and PODD down 4.29%, indicating a stock-specific reaction rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Innovation & patents | Positive | -0.3% | EPO data showing Philips as top medtech patent filer and Dutch applicant. |
| Mar 23 | AGM announcement | Positive | +2.1% | Convening AGM 2026 with board and CEO re-appointment proposals and agenda. |
| Mar 23 | Board changes | Positive | +2.1% | New Supervisory Board appointment and multiple re-appointments including CEO. |
| Mar 17 | Consumer campaign | Positive | +0.2% | Philips Sonicare oral health awareness event and new electric toothbrush claims. |
| Mar 11 | Digital pathology | Positive | -0.5% | Cloud-enabled IntelliSite Pathology Solution launch on HealthSuite platform. |
Recent company-specific news often triggered modest price moves, with a mix of aligned and divergent reactions to generally positive headlines.
Over recent months, Philips has highlighted innovation and portfolio expansion, including leading European medtech patent rankings, digital pathology growth on HealthSuite, and product-focused campaigns like Sonicare’s World Oral Health Night. Governance news around AGM preparations and board/CEO re-appointments also featured. The new FDA 510(k) clearance for AI-assisted DeviceGuide in mitral valve repair continues this theme of image-guided, AI-enabled healthcare solutions enhancing Philips’ procedural cardiology offerings.
Market Pulse Summary
This announcement highlights FDA 510(k) clearance for Philips’ AI-enabled DeviceGuide within its EchoNavigator platform, targeting complex mitral transcatheter edge-to-edge repair procedures that address more than 35 million MR patients worldwide. It reinforces Philips’ focus on connected cardiology and advanced imaging, following recent moves in digital pathology and innovation leadership. Investors may watch clinical adoption rates, integration with existing cath-lab workflows, and further regulatory or partnership updates around cardiology solutions.
Key Terms
510(k) clearance regulatory
mitral regurgitation medical
AI-generated analysis. Not financial advice.
March 26, 2026
- Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]
- DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that assists physicians during one of interventional cardiology’s most technically demanding procedures – repairing leaking mitral valves through a minimally invasive approach.
DeviceGuide was developed in close collaboration with Edwards Lifesciences, the global leader in structural heart innovation, aligning Philips’ imaging and AI expertise with Edwards’ expertise in valvular heart therapy development. Together, the companies have innovated image guidance of the mitral transcatheter edge-to-edge repair (M-TEER) workflow to make these complex minimally invasive heart valve repair procedures more intuitive and streamlined.
DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans, one of the world’s leading forums for cardiovascular innovation.
Transforming treatment for a common heart condition
A leaking mitral valve, known as mitral regurgitation (MR), affects more than 35 million adults worldwide and over 2 million in the U.S. [3, 4]. Minimally invasive transcatheter techniques such as M-TEER offer an alternative to open heart surgery in selective patient populations.
During M-TEER procedures, physicians make a small skin incision to access a vein which allows the introduction of a catheter to the heart to deliver a repair device to the diseased mitral valve. Because the mitral valve is inherently a complex and heterogeneous structure, transcatheter repair of the valve requires experienced physicians positioning the device delivery system, and physicians guiding the placement of the device. In guiding and positioning the repair device, the intraprocedural heart team must interpret both X-ray and ultrasound images on multiple screens, communicate and coordinate movements between two operators, and make precise adjustments to grasp the moving valve leaflets and then confirm the result in real time. The process demands accuracy, coordination, and experience from the entire team – and this is where DeviceGuide can help with navigation guidance.
How AI assists inside the beating heart
Built on Philips’ EchoNavigator echo-fluoro fusion technology, which combines live echocardiography images from Philips EPIQ CVxi cardiovascular platform with live X-ray images from Philips Azurion image-guided therapy system, DeviceGuide brings real-time AI guidance directly into the procedure room.
The software’s AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device, combining live ultrasound and X-ray images into a single, integrated view. This helps clinicians navigate and position the device with greater clarity and confidence.
“The AI software serves as an assistive tool; the physician always remains in control. This isn’t about replacing expertise – it’s about amplifying it,” explains Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips. “By embedding AI into the procedure, DeviceGuide gives physicians an extra pair of eyes, helping them treat more patients safely and confidently.”
Collaboration with clinical partners
In developing DeviceGuide, Philips and Edwards worked closely with investigational sites in Europe and the U.S., including a team at the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Irving Medical Center, led by interventional cardiologist Susheel Kumar Kodali, MD, director, and Rebecca T. Hahn, MD, director of interventional echocardiography.
“In helping to guide mitral repair procedures, one of my roles as an echocardiographer is to help the interventional cardiologist understand the complex anatomy of the valve which will determine the orientation, trajectory and position of the repair device relative to the target and the surrounding structures,” said Dr. Hahn. “Since AI auto-aligns imaging to the device in real time and continuously informs the interventionalist about the location of the device in space on the imaging screen, it minimizes unnecessary repositioning of the imaging window, streamlines procedural guidance and may improve the precision of device implantation.”
“DeviceGuide provides me with a visual overlay, trajectory line and orientation line of the therapy device in both live 3D echo and fluoroscopic images during mitral valve repair procedures,” said Dr. Kodali. “Having a single, intuitive presentation of real-time target, orientation and auto device-aligned views simplifies this procedure and improves team communication.”
Supporting teams in real time
“Structural heart procedures are among the fastest-growing areas in cardiology, and also among the most complex,” said Mark Stoffels, Business Leader, Image Guided Therapy Systems at Philips. “By assisting physicians with real-time visualization and navigation inside the beating heart, DeviceGuide helps them manage that complexity, and perform procedures more confidently, with the ultimate goal to treat more patients effectively. It fits seamlessly into cath-lab workflows and gives the entire team a shared view of the procedure, improving coordination and confidence.”
Part of Philips’ connected cardiology ecosystem
DeviceGuide extends Philips’ connected cardiology portfolio that helps physicians care for heart patients from diagnosis through recovery. It also represents a step toward Philips’ vision of the AI-powered cath lab of the future where imaging, devices, and real-time data are intelligently connected to reduce procedural complexity and improve consistency. In hospitals, Philips systems already bring together ultrasound, X-ray, and real-time data into a unified workflow to guide minimally invasive procedures. Building on this foundation, intelligent software solutions such as DeviceGuide help care teams navigate complex structural heart interventions with greater clarity and coordination, serving as an assistive “copilot” in the procedure room.
After treatment, Philips connected monitoring tools extend care beyond the cath lab, helping care teams detect complications early and support recovery. Together, these innovations create a connected cardiology ecosystem that helps care teams diagnose earlier, treat less invasively, improve procedural efficiency, and support recovery – improving outcomes and experiences for heart patients everywhere.
Availability
DeviceGuide enabled by EchoNavigator is FDA 510(k) cleared in the United States. Commercial availability is subject to market release and applicable regulatory requirements. DeviceGuide is currently intended for use with the Edwards PASCAL Ace Mitral Valve Repair System. Availability outside the U.S. varies by country and regulatory status.
A recent first-in-human publication in JACC: Case Reports describes early clinical experience using DeviceGuide for AI-supported imaging guidance during mitral transcatheter edge-to-edge repair procedures.
Read more on how Philips DeviceGuide works here.
Philips DeviceGuide enabled by EchoNavigator R5 is not available for sale or use in all countries. Its availability is subject to local regulatory clearance and market release. Please contact your Philips representative for details on product availability in your region.
Dr. Hahn reports Institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Philips North America LLC, and from Edwards Lifesciences Corporation.
Dr. Kodali discloses consulting payments from Philips North America LLC and reports Institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Edwards Lifesciences Corporation.
REFERENCES:
[1] DeviceGuide is currently intended for use only with the Mitral TEER Therapy Device (Edwards PASCAL Ace);
Hahn RT, Biaggi P, Corti R et al. Mitral Transcatheter Edge-to-Edge Repair Using Novel Augmented Imaging Software. JACC: Case Reports 2025;30:106160.
[2] DeviceGuide assists physicians in visualizing and navigating the repair device within the heart. It supports, but does not perform, the therapeutic procedure itself;
Biaggi P, Corti R, Gaemperli O et al. Artificial intelligence based fusion imaging streamlining mitral transcatheter edge-to-edge repair. European Heart Journal - Imaging Methods and Practice 2026;4.
[3] MDPI
[4] CDC
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com
Avi Dines
Philips North America
Tel: +1 781 690 3814
E-mail: avi.dines@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Physician using DeviceGuide with EchoNavigator 5
- Philips DeviceGuide with EchoNavigator 5 Screen
- DeviceGuide with EchoNavigator 5
FAQ
What did Philips (PHG) announce about FDA clearance on March 26, 2026?
How does DeviceGuide assist physicians during mitral transcatheter edge-to-edge repair (M-TEER)?
Is Philips DeviceGuide commercially available in the U.S. after the 2026 FDA clearance?
Which mitral repair device is DeviceGuide intended to be used with (PHG)?
Will Philips present DeviceGuide at medical conferences in 2026?
